The leading provider of hemp-derived CBD for retail pharmacies in the US, Ecofibre’s Ananda Health division, has appointed MEDISCA to be the exclusive pharmaceutical compounding distributor of Ananda Professional products in the United States, Canada and Australia.
MEDISCA provides turnkey solutions to the pharmaceutical compounding industry and allied health care professionals worldwide. Through its global partners, LP3 Network and MEDISCA Network, MEDISCA offers resources for prescribers, pharmacists and pharmacy technicians engaged in personalized medicine by offering educational training, products, and support.
“CBD is an exciting new category that still requires significant research and education to ensure it can help as many patients as possible. In conjunction with Ananda Health, we are very excited to be able to give our pharmacists access to the research, tools and training to improve patient outcomes,” comments Panagiota Danopoulos, SVP Global Strategy and Innovation at MEDISCA.
“MEDISCA has been closely monitoring the CBD segment over the past several years and we have seen awareness and demand increase for compounding pharmacists across many geographies. To ensure that we can provide our pharmacists the best-in-class CBD product range we are very pleased to announce our exclusive distribution partnership with Ananda Health,” continues Danopoulos.
In the United States, Ananda Health is the leading provider of hemp-derived CBD for retail pharmacies. The Company produces nutraceutical products for human and pet consumption, as well as topical creams and salves.
David Neu, CEO of Ananda Health states, “We could not be more proud to partner with the global leader in the pharmaceutical compounding industry. MEDISCA has over 30 years of experience in the industry and both of our organizations have core values that are deeply aligned around education, quality and customer care.”
Neu continued “This partnership is one of the most important milestones in the professionalization of the CBD industry. This is the first time a multinational distributor will be carrying ingestible hemp-derived CBD products.”
Ananda Health is driving the use of hemp-derived CBD products across a variety of different clinical trials. In 2020, the Company began patient enrolment in a phase II clinical trial using Ananda Health hemp-derived cannabidiol.
The purpose of the study is to assess the efficacy of a hemp-based CBD product, Ananda Health Spectrum gelcaps, on the severity and duration of chemotherapy-induced peripheral neuropathy (CIPN) among breast, colon, and ovarian cancer patients who received common types of neurotoxic chemotherapy.